Tags

Type your tag names separated by a space and hit enter

Steatosis in hepatitis C virus infection. Response to anti-viral therapy.
J Gastrointestin Liver Dis. 2006 Jun; 15(2):117-24.JG

Abstract

BACKGROUND

Steatosis is a frequent feature of hepatitis-C-virus (HCV) infection. Steatosis may be an important cofactor in both accelerating fibrosis and increasing liver necroinflammatory activity in chronic hepatitis C. Several studies suggested that steatosis induces resistance to interferon and ribavirin combination treatment.

AIM

to assess the prevalence of steatosis in chronic HCV-infection and the host factors associated with steatosis, to estimate the impact of steatosis on liver fibrosis, and to evaluate the response to antiviral therapy in patients with HCV-infection and steatosis.

MATERIAL AND METHOD

A retrospective study was performed on 37 patients with chronic active HCV-infection treated with interferon and ribavirin: 21 women and 16 men, mean age 46.97 years. Presence of metabolic syndrome was assessed according to the ATPIII criteria. Cobas Amplicor HCV-Test was used to detect HCV-RNA. Steatosis was graded using the Brunt system.

RESULTS

Prior to the antiviral treatment, steatosis was present in 26 out of 37 patients (70%). Patients with steatosis were older, especially those with associated metabolic syndrome. Fibrosis stage was significantly advanced in patients with steatosis. Lower baseline viremia correlated with sustained response both in patients with and without steatosis. Absence of baseline steatosis was associated with higher biochemical and virological sustained response. None of the patients with metabolic syndrome had a sustained response to antiviral therapy. In all patients, the stage of fibrosis did not significantly improve 6 months after cessation of the antiviral treatment.

CONCLUSION

Steatosis is a frequently encountered histological feature in chronic HCV-infection. It is associated with older age, lower virologic response and worsening fibrosis irrespective of antiviral treatment.

Authors+Show Affiliations

3rd Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Str. Croitorilor no. 19-21, 400162 Cluj-Napoca, Romania.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16802005

Citation

Szanto, Paula, et al. "Steatosis in Hepatitis C Virus Infection. Response to Anti-viral Therapy." Journal of Gastrointestinal and Liver Diseases : JGLD, vol. 15, no. 2, 2006, pp. 117-24.
Szanto P, Grigorescu M, Dumitru I, et al. Steatosis in hepatitis C virus infection. Response to anti-viral therapy. J Gastrointestin Liver Dis. 2006;15(2):117-24.
Szanto, P., Grigorescu, M., Dumitru, I., & Serban, A. (2006). Steatosis in hepatitis C virus infection. Response to anti-viral therapy. Journal of Gastrointestinal and Liver Diseases : JGLD, 15(2), 117-24.
Szanto P, et al. Steatosis in Hepatitis C Virus Infection. Response to Anti-viral Therapy. J Gastrointestin Liver Dis. 2006;15(2):117-24. PubMed PMID: 16802005.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Steatosis in hepatitis C virus infection. Response to anti-viral therapy. AU - Szanto,Paula, AU - Grigorescu,Mircea, AU - Dumitru,Iuliana, AU - Serban,Alexandru, PY - 2006/6/28/pubmed PY - 2006/8/19/medline PY - 2006/6/28/entrez SP - 117 EP - 24 JF - Journal of gastrointestinal and liver diseases : JGLD JO - J Gastrointestin Liver Dis VL - 15 IS - 2 N2 - BACKGROUND: Steatosis is a frequent feature of hepatitis-C-virus (HCV) infection. Steatosis may be an important cofactor in both accelerating fibrosis and increasing liver necroinflammatory activity in chronic hepatitis C. Several studies suggested that steatosis induces resistance to interferon and ribavirin combination treatment. AIM: to assess the prevalence of steatosis in chronic HCV-infection and the host factors associated with steatosis, to estimate the impact of steatosis on liver fibrosis, and to evaluate the response to antiviral therapy in patients with HCV-infection and steatosis. MATERIAL AND METHOD: A retrospective study was performed on 37 patients with chronic active HCV-infection treated with interferon and ribavirin: 21 women and 16 men, mean age 46.97 years. Presence of metabolic syndrome was assessed according to the ATPIII criteria. Cobas Amplicor HCV-Test was used to detect HCV-RNA. Steatosis was graded using the Brunt system. RESULTS: Prior to the antiviral treatment, steatosis was present in 26 out of 37 patients (70%). Patients with steatosis were older, especially those with associated metabolic syndrome. Fibrosis stage was significantly advanced in patients with steatosis. Lower baseline viremia correlated with sustained response both in patients with and without steatosis. Absence of baseline steatosis was associated with higher biochemical and virological sustained response. None of the patients with metabolic syndrome had a sustained response to antiviral therapy. In all patients, the stage of fibrosis did not significantly improve 6 months after cessation of the antiviral treatment. CONCLUSION: Steatosis is a frequently encountered histological feature in chronic HCV-infection. It is associated with older age, lower virologic response and worsening fibrosis irrespective of antiviral treatment. SN - 1841-8724 UR - https://www.unboundmedicine.com/medline/citation/16802005/Steatosis_in_hepatitis_C_virus_infection__Response_to_anti_viral_therapy_ L2 - https://www.jgld.ro/jgld/index.php/jgld/article/view/2006.2.2 DB - PRIME DP - Unbound Medicine ER -